Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback